February 13, 2025

Therapeutic Designer Peptide to Combat Acute Heart Muscle Weakness

Therapeutic Designer Peptide to Combat Acute Heart Muscle Weakness

Researchers of the Heidelberg University, Heidelberg University Hospital (UKHD) and Heidelberg Institute for Theoretical Studies (HITS) have developed a synthetic peptide based on the natural protein S100A1, a nearly universal “fuel” for weakened hearts. The researchers combined computer-aided methods with lab studies to investigate the therapeutic effect of the so called S100A1ct peptide molecule. The results have been published in the journal “Circulation”.

Source: Heidelberg University Hospital

The “Molecular and Cellular Modeling” group led by Rebecca Wade was part of the project. The approach was to integrate experiments on heart muscle cells and animals and computational molecular modeling. “Our lab developed a customized computer-aided modeling pipeline for this project to model the molecular structure of the peptide and interactions with the predicted molecular effectors in the diseased heart cells”, Wade says. “The computational modeling guided the design of specific experiments to investigate the molecular mechanisms.”

The framework for the successful cooperation was provided by the Informatics for Life (I4L) Initiative, which was funded by the Klaus Tschira Foundation. The project received further financial support from the German Center for Cardiovascular Research with translational project funding from the Federal Ministry of Education and Research from the “Preclinical Confirmatory Studies” program.

For more information see the press release of the Heidelberg University Hospital:
https://www.klinikum.uni-heidelberg.de/newsroom/en/therapeutic-designer-peptide-to-combat-acute-heart-muscle-weakness/

Publication:

Kehr D, Ritterhoff J, Glaser M, et al. S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models. Circulation. Published online November 21, 2024. doi:10.1161/CIRCULATIONAHA.123.066961

Scientific Contact:

Prof. Dr. Patrick Most 
Division of Molecular and Translational Cardiology
Department of Internal Medicine III 
Heidelberg University Hospital
Heidelberg Medical Faculty of Heidelberg University
patrick.most@med.uni-heidelberg.de

Prof. Dr. Rebecca Wade
Group Leader `Molecular and Cellular Modeling´
Heidelberg Institute for Theoretical Studies (HITS)
Center of Molecular Biology of Heidelberg University (ZMBH)
Heidelberg Medical Faculty of Heidelberg University

Press Contact:
Dr. Stefanie Seltmann
Head of Communications
Heidelberg University Hospital (UKHD)
presse@med.uni-heidelberg.de

Dr. Peter Saueressig
Head of Communications
Heidelberg Institute for Theoretical Studies (HITS)
comms@h-its.org

Our latest News

discover more
GeneNovate® 2026: Heidelberger Forschende stärken unternehmerisches Denken für die nächste Generation von Gen- und Zelltherapien

GeneNovate® 2026: Heidelberger Forschende stärken unternehmerisches Denken für die nächste Generation von Gen- und Zelltherapien

Heidelberg, Juni 2026 – Mit dem Final Event von GeneNovate® am 25. Juni in der Münchner Residenz endet die dritte Runde des bundesweiten Entrepreneurship-Programms der Nationalen Strategie für gen- und zellbasierte Therapien (Nationale Strategie GCT). Im Rahmen der Abschlussveranstaltung präsentierten Wissenschaftlerinnen und Wissenschaftler aus ganz Deutschland ihre innovativen Geschäftsideen mit Potenzial für zukünftige Gesundheitslösungen und […]

Post-COVID Syndrome: Study Finds Hemodialysis Offers No Benefit to Patients

Post-COVID Syndrome: Study Finds Hemodialysis Offers No Benefit to Patients

A study recently published in *The Lancet Regional Health – Europe* calls into question the benefits of immunoadsorption—a specialized form of blood purification—for post-COVID syndrome. While the autoantibodies, which are thought to be a possible cause of the condition, can be removed from the blood, this does not improve the symptoms of those affected. The […]

Universität Heidelberg: Humboldt Professorship for Leading International Researcher

Universität Heidelberg: Humboldt Professorship for Leading International Researcher

Highly endowed research prize goes to Harvard scientist Mathias Lichterfeld on the proposal of Ruperto Carola In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp